Onco-Innovations' PKNP Technology Demonstrates Low Toxicity and High Safety Profile in Preclinical Study

Onco-Innovations Limited (CSE:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H,WKN:A3EKSZ), a Canadian-based company dedicated to cancer research and treatment, has announced promising results from a preclinical study on its second-generation nanoparticle formulation of Polynucleotide Kinase 3'-Phosphatase (PNKP) Compound. The study, conducted by researchers at the University of Alberta, Canada, demonstrated that the Technology was well-tolerated in mice with colorectal cancer, even at therapeutic doses, with no evidence of toxicity such as weight loss or adverse effects. This finding highlights the potential of Onco-Innovations' PKNP Technology to provide safer and more effective cancer treatments with fewer side effects.

In the in vivo study, mice with colorectal cancer tumors were treated over a 22-day period with Onco's PKNP nanoparticle formulation (NP/A83), while a control group received placebo injections. The study involved both in vitro and in vivo evaluations of a nano-encapsulated potent lead PNKP inhibitor, which was tested as a new targeted therapy for PTEN-deficient colorectal cancer (CRC). Throughout the study, the treatment was well tolerated, with no evidence of toxicity observed in the test subjects. Biochemical and histopathological examination of major organs confirmed the absence of toxicity in mice treated with the nanoparticle formulation. Dose-escalating toxicity studies on healthy CD-1 mice revealed that both free and nano-encapsulated PNKP inhibitors were safe at doses of ≤50 mg/kg, based on weight changes and blood analysis.

Ensuring a low toxicity profile is essential for developing safer and more effective cancer treatments. By demonstrating minimal toxicity in preclinical models, Onco's Technology shows promise for pursuing therapies with fewer side effects. Under Health Canada regulations, drugs must undergo rigorous testing in animal models (in vivo) or in cell cultures (in vitro) to assess toxicity at doses intended to produce therapeutic effects.

"The study has shown that our PKNP technology has promise for future therapeutic development, particularly due to its low toxicity profile. The ability of this technology to deliver enhanced PNKP inhibition with minimal side effects lays a solid foundation for our continued research and development plans. We are excited about the future of this compound and its potential to provide safer and more effective therapies," said Thomas O'Shaughnessy, CEO of the Company.

Onco-Innovations is committed to cancer research and treatment, specializing in oncology. The company has secured an exclusive worldwide license to patented groundbreaking technology that targets solid tumours, setting new standards in cancer treatment. By pursuing innovative solutions and advanced therapies, Onco-Innovations aims to improve patient outcomes and offer hope in the fight against cancer.



In conclusion, Onco-Innovations' PKNP Technology has demonstrated a low toxicity profile and high safety profile in preclinical studies, positioning it as a promising candidate for further research and development in cancer treatment. As the company continues its research and development efforts, the potential benefits and risks associated with this Technology will evolve, and investors should monitor these developments closely. The successful commercialization of this Technology will depend on navigating regulatory hurdles and maintaining a strong safety profile throughout the development process.